Percheron Therapeutics Limited

PER

AU0000317281

Biotechnology & Medical Research

End-of-day quote Australian S.E. Other stock markets 06:00:00 2024-05-09 pm EDT			5-day change	1st Jan Change
0.075 ^AUD	-1.32%		-2.60%	+27.12%

May. 06	WHO Selects International Nonproprietary Name for Percheron Therapeutics' Drug Candidate ATL1102	MT
Feb. 28	Percheron Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	CI

Antisense Therapeutics Limited Announces Change of Registered Office and Principal Place of Business

January 13, 2021 at 08:41 pm EST

Antisense Therapeutics Limited advise that as of immediate effect its registered office and principal place of business will change to: Level 1, 14 Wallace Avenue, TOORAK VIC 3142, AUSTRALIA.

Latest news about Percheron Therapeutics Limited

WHO Selects International Nonproprietary Name for Percheron Therapeutics' Drug Candidate ATL1102	May. 05	MT
Percheron Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 28	CI
Dimerix Appoints Nonexecutive Chair	Nov. 19	MT
Antisense Therapeutics Limited has Changed its Name to Percheron Therapeutics Limited	Nov. 15	CI
Antisense Therapeutics Launches Share Sale Facility for Unmarketable Parcels	23-10-09	MT
Antisense Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-25	CI
Antisense Therapeutics' Share Purchase Plan Raises AU$3.3 Million	23-08-21	MT
Antisense Therapeutics Appoints CEO/Managing Director	23-08-06	MT
Antisense Therapeutics Limited Announces Commencement of James Garner as Chief Executive Officer, Effective 7 August 2023	23-08-06	CI
Antisense Therapeutics Limited Announces Management Changes	23-08-06	CI
Antisense Therapeutics to Launch Share Purchase Plan; Shares Plunge 8%	23-07-20	MT
Antisense Therapeutics Limited Receives MHRA Approval for ATL1102 Phase IIb DMD Clinical Trial in UK	23-06-27	CI
Antisense Therapeutics Doses First Patient in Duchenne Muscular Dystrophy Drug Trial; Shares Jump 11%	23-06-07	MT
Antisense Therapeutics Appoints CEO/Managing Director	23-05-08	MT
Antisense Therapeutics Limited Announces the Appointment of James Garner as Chief Executive Officer, Effective 07 August 2023	23-05-07	CI
Antisense Therapeutics Limited Appoints James Garner as Managing Director and to Join the Board as a Non-Executive Director	23-05-07	CI
Antisense Therapeutics Begins Dosing in Toxicology Study for Muscular Dystrophy Treatment	23-03-14	MT
Antisense Therapeutics Limited Announces the Commencement of Dosing in the Nine-Month Chronic Monkey Toxicology Study of ATL1102	23-03-13	CI
Antisense Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-22	CI
Antisense Therapeutics Secures Turkish Clearance for Phase 2 Muscular Dystrophy Trial	23-02-14	MT
Antisense Therapeutics Limited Receives Regulatory Authority Approval from the Turkish Medicines and Medical Device Agency	23-02-13	CI
Antisense Therapeutics Starts Muscular Dystrophy Animal Study	23-02-13	MT
Antisense Therapeutics Limited Commences the Second Phase (Chronic Setting) of Its Program to Study the Effects of an Antisense Oligonucleotide to CD49d (Mouse Equivalent of ATL1102) in a LGMDR2 Animal Model of Dysferlin Deficiency	23-02-12	CI
Antisense Therapeutics Limited Reports Initial Positive Muscle Functional Data from A DMD	23-01-31	CI
Antisense Therapeutics Files Trial Applications for Phase 2b Trial	22-12-19	MT

Chart Percheron Therapeutics Limited

Duration

Period

More charts

Percheron Therapeutics Limited, formerly Antisense Therapeutics Limited, is a biotechnology company. The Company is engaged in developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The Companyâs products include ATL1102 for Duchenne muscular dystrophy (DMD), ATL1103 for Acromegaly, and ATL1102 for Multiple Sclerosis (MS). ATL1102, is an antisense inhibitor targeting very late antigen 4 (VLA-4), an immune cell molecule. ATL1103 is a second-generation antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood and is a potential treatment for diseases associated with excessive growth hormone action. By inhibiting GHr production, ATL1103 in turn reduces IGF-I levels in the blood (serum). The Company is conducting a Phase II clinical trial of ATL1102 in DMD patients.

Sector

Biotechnology & Medical Research

Calendar

2024-08-27 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Percheron Therapeutics Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.075 AUD

Average target price

0.25 AUD

Spread / Average Target

+233.33%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
PERCHERON THERAPEUTICS LIMITED	+27.12%	44.65M
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+0.23%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.80%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs

Percheron Therapeutics Limited

Equities

PER

AU0000317281

Biotechnology & Medical Research

Antisense Therapeutics Limited Announces Change of Registered Office and Principal Place of Business

Latest news about Percheron Therapeutics Limited

Chart Percheron Therapeutics Limited

Company Profile

Income Statement Evolution

Ratings for Percheron Therapeutics Limited

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs